TORONTO, Aug. 8, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") is pleased to announced the appointment of Dr. Michael Gross to the Company's Board of Directors.
Dr. Gross is a Professor of Orthopaedic surgery at Dalhousie University in Halifax, Nova Scotia and Medical Director of the regional tissue bank which is regulated by 6 different bodies. He brings to the Company a wealth of public company experience, serving as Lead Director for Brigus Gold (TSX:BRD), a TSX listed gold mining company, where he also chairs the Compensation and Governance committees. He is considered financially literate and has chaired an audit committee for Linear Metals Corporation (TSX:LRM) in the past. He completed the Rotman Directors Education Program as co-valedictorian, holds the IcD designation and is a member of the Institute of Corporate Directors. He is involved in several entrepreneurial start up companies including Boomerswork.ca where he is Chairman of the Board, and Impetus Innovations Inc, a company which is developing "smart" orthopaedic implant technologies that provide better patient outcomes and lower healthcare costs. Dr Gross is also a board member of the First Angels investor group in Halifax.
Biosign CEO Robert Kaul stated: "We are fortunate to be able to welcome Dr Gross to our team. As a very experienced physician & surgeon, he brings to us a strong body of medical knowledge, and his advice and counsel will be instrumental to our future as a leading provider of healthcare solutions. As a corporate director, he offers outstanding credentials, passion and energy. As a successful entrepreneur in his own right, Dr Gross also offers Biosign access to key networks in the fields of finance, medical device innovation and technology. Along with the recently announced Biosign Critical Care Validation Project (CCVP) at the University of New Brunswick, the appointment of Dr Gross is a further vindication of our well-received restructuring plan, and a strong endorsement of the leadership and direction of the management team."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave™ Health Monitor and the Healthanywhere™ Patient monitoring / self-care platform. The Company's Pulsewave™ Health Monitor solution enables Pulse data collection for cardiovascular clinical decision support and self-care, while its Healthanywhere™ solution offers industry-leading remote patient monitoring and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
Biosign Contact Information
Robert Kaul
Chief Executive Officer
Biosign Technologies
Phone: (416) 218-9800 ext. 201
Email: [email protected]
Share this article